35 results
8-K
EX-1.1
SYRS
Syros Pharmaceuticals Inc.
19 Dec 23
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
4:59pm
, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
25 May 23
Regulation FD Disclosure
5:10pm
infusions up to ~2,000 patients are diagnosed with APL in the US and EU Opportunity to reduce treatment burden, increase annually access and reduce health … care costs FS26 Acute Promyelocytic Leukemia Facts, 2015; NCCN AML treatment guidelines (Nov 2020); Trisenox (arsenic trioxide) USPI 15
SY-2101 has
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
12 Dec 22
Regulation FD Disclosure
7:48am
opportunity to reduce treatment burden, increase access, reduce health care costs and utilization Current standard of care IV ATO oral ATRA80% Cure
D
uv9ll4l ewcpb3
21 Sep 22
$129.84M in equity / options, sold $129.84M, 19 investors
5:07pm
424B3
voeyz76zlbx1myncqnb
8 Aug 22
Prospectus supplement
5:47pm
S-4
u4ar9w 8n
18 Jul 22
Registration of securities issued in business combination transactions
7:58am
425
rww n34fu9
6 Jul 22
Business combination disclosure
4:30pm
8-K
EX-99.2
ev9jhs2k74gin1kgn
6 Jul 22
Other Events
4:27pm
8-K
EX-99.1
sltp74sn3i8z6il
6 Jul 22
Other Events
4:27pm
425
yt3zpaio55c4ebmixwg
5 Jul 22
Business combination disclosure
7:14am
8-K
EX-2.1
au05q wop8db
5 Jul 22
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7:07am
8-K
EX-99.1
m11k49e15sxeu dx
7 Jun 22
Submission of Matters to a Vote of Security Holders
7:31am
8-K
EX-99.1
j3fm hczhy9udxvv1wk1
10 Jan 22
Regulation FD Disclosure
7:06am
8-K
EX-99.1
dta2kz9p
26 May 21
Regulation FD Disclosure
8:30am
8-K
EX-99.1
r69t 2nbcc6f
25 Feb 21
Regulation FD Disclosure
7:01am
8-K
EX-1.1
0z0yozs46bs2 kpsm
20 Jan 21
Syros Announces Proposed Offering of Common Stock
4:04pm